Description
Cefastar CV Dry Syrup (Cefpodoxime Proxetil) for Dogs and Cats
Advanced Antibiotic Support for Pets
Pettivo presents Cefastar CV Dry Syrup, a veterinary antibiotic formulation containing Cefpodoxime Proxetil, specially designed to help manage a broad range of bacterial infections in dogs and cats. This easy-to-administer oral dry syrup provides effective antibacterial support and helps pets recover comfortably from common infections.
Cefpodoxime Proxetil is a broad-spectrum cephalosporin antibiotic known for its effectiveness against susceptible bacteria affecting the skin, respiratory tract, urinary tract, and soft tissues in pets.
Key Benefits of Cefastar CV Dry Syrup
- Contains Cefpodoxime Proxetil
- Broad-spectrum antibacterial support
- Helps manage skin and soft tissue infections
- Useful in respiratory and urinary tract infections
- Supports faster recovery from bacterial illnesses
- Easy-to-administer dry syrup formulation
- Suitable for dogs and cats
- Veterinary-recommended antibiotic support
Common Uses
- Skin and wound infections
- Respiratory tract infections
- Urinary tract infections
- Ear infections caused by susceptible bacteria
- Post-surgical bacterial infection management
Suitable For
- Dogs and cats of different breeds and sizes
- Puppies and kittens as advised by veterinarians
- Pets requiring oral antibiotic therapy
Why Choose Cefastar CV Dry Syrup?
Cefastar CV Dry Syrup offers reliable antibacterial support with Cefpodoxime Proxetil, helping veterinarians effectively manage common bacterial infections in pets. Its palatable dry syrup form makes administration easier, especially for young or small pets.
Directions for Use
Reconstitute and administer as directed by a veterinarian. Complete the full prescribed course for effective infection management and improved recovery.
Storage Instructions
- Store in a cool and dry place
- Protect from moisture and direct sunlight
- Keep bottle tightly closed after use
- Keep out of reach of children and pets




Reviews
There are no reviews yet.